RPP # | Requirement Topic | Description | Requiring Office | Submission Due Date |
---|---|---|---|---|
RPP-24-06-DxR2 (3/27/2024) | Biothreat Diagnostic Rapid Response | Through this Request for Project Proposals (RPP) BARDA is seeking to address its product portfolio capability readiness gaps for rapid biothreat diagnostic test development and ready-production capacity to quickly produce tests in lieu of stockpiling. Biothreat tests will be developed and pilot program(s) will be established to assess the feasibility of rapid response capabilities, leveraging existing domestic manufacturing capacities. | 5/17/2024 1pm Eastern | |
Q3FY24 RPP | Project NextGen: On Demand Manufacturing | Under the Project NextGen Enablers Program, BARDA aims to advance technologies that decrease costs, speed production, and improve access for vaccines. The vision for on-demand manufacturing is to develop a portable, smaller footprint, end-to-end manufacturing system that can produce vaccines on-demand in GMP conditions. This program will make a meaningful step towards this envisioned end state by supporting the development of new manufacturing technologies that improve the speed, scale, cost, yield, and flexibility of on-demand capabilities, while maintaining high levels of product quality. The effort notionally plans to support a prototype and development phase and, if criteria for success are met, an optimization and final demonstration phase. | ||
Q3-Q4FY24 | mRNA Vaccine Platform Production Capability for Rapid Pandemic and Priority Threat Response | The requirements for mRNA Vaccine Platform Production Capability for Rapid Pandemic and Priority Threat Response are being redefined. As we redefine the requirements, we will actively communicate updates. | IEID | TBD |
RPP-24-03-Treatment (02/21/2024) | Project NextGen: Therapeutics | To partner with developers and other organizations to advance the clinical development of Next-Generation Therapeutics for COVID-19, specifically treatment. | 5/13/2024 1pm Eastern |
RPP # (Date) | Requirement Topic | Closed Date |
---|---|---|
RPP-24-05-NGClinMfg (01/16/2024) | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines | 04/19/2024 |
RPP-24-04-NGVxStats (2/23/2024) | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis | 03/27/2024 |
RPP-24-04-NGVxAssays (2/15/2024) | NextGen Vaccines: Immune Assays | 3/22/2024 1pm Eastern |
RPP-24-02-Retail (2/2/2024) | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 03/20/2024 |
RPP-24-03-PrEP (11/30/2023) | COVID-19 Monoclonal Antibody Therapeutics for PrEP | 01/19/2024 |
RPP-24-02-HomeFocus (11/30/2023) | Enabling Technology – Decentralized Clinical Trial – Home Focus | 01/19/2024 |
RPP-24-04-NGVx (11/30/2023) | NextGen Vaccinations: Phase 2B Clinical Trial Execution | 01/10/2024 |
RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 12/4/2023 |